HRP20230267T1 - Pripravci za liječenje hipertenzije - Google Patents
Pripravci za liječenje hipertenzije Download PDFInfo
- Publication number
- HRP20230267T1 HRP20230267T1 HRP20230267TT HRP20230267T HRP20230267T1 HR P20230267 T1 HRP20230267 T1 HR P20230267T1 HR P20230267T T HRP20230267T T HR P20230267TT HR P20230267 T HRP20230267 T HR P20230267T HR P20230267 T1 HRP20230267 T1 HR P20230267T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- dose
- use according
- indapamide
- telmisartan
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 8
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 4
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims 4
- 229960004005 amlodipine besylate Drugs 0.000 claims 4
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims 4
- 229960004569 indapamide Drugs 0.000 claims 4
- 229960005187 telmisartan Drugs 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Furan Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (7)
1. Farmaceutski pripravak za uporabu u liječenju hipertenzije koji sadrži:
(a) telmisartan;
(b) indapamid; i
(c) amlodipin besilat;
naznačen time, što je doza telmisartana oko 8 mg do 12 mg, doza indapamida je oko 0.5 mg do 0.75 mg, i doza amlodipin besilata je oko 1 mg do 1.5 mg i
pri čemu farmaceutski pripravak ne sadrži inhibitor angiotenzin-konvertirajućeg enzima ili njegovu farmaceutski prihvatljivu sol, beta-blokator ili njegovu farmaceutski prihvatljivu sol, sredstvo za regulaciju lipida, sredstvo koje modificira funkciju trombocita, sredstvo za snižavanje homocisteina u serumu, ili njihovu kombinaciju.
2. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, što je doza indapamida oko 0.625 mg.
3. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, što je doza amlodipin besilata oko 1.25 mg.
4. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, što je doza telmisartana oko 10 mg.
5. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, što je doza telmisartana oko 10 mg, doza indapamida je oko 0.625 mg, i doza amlodipin besilata je oko 1.25 mg.
6. Farmaceutski pripravak za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, što je farmaceutski pripravak pogodan za oralnu primjenu.
7. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 6, naznačen time, što je farmaceutski pripravak u obliku pilule, tablete ili kapsule.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450324P | 2017-01-25 | 2017-01-25 | |
| PCT/IB2018/000083 WO2018138578A1 (en) | 2017-01-25 | 2018-01-23 | Compositions for the treatment of hypertension |
| EP18745362.6A EP3573620B1 (en) | 2017-01-25 | 2018-01-23 | Compositions for the treatment of hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230267T1 true HRP20230267T1 (hr) | 2023-06-09 |
Family
ID=62979058
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240701TT HRP20240701T1 (hr) | 2017-01-25 | 2018-01-23 | Pripravci za uporabu u liječenju hipertenzije |
| HRP20230267TT HRP20230267T1 (hr) | 2017-01-25 | 2018-01-23 | Pripravci za liječenje hipertenzije |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240701TT HRP20240701T1 (hr) | 2017-01-25 | 2018-01-23 | Pripravci za uporabu u liječenju hipertenzije |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10322117B2 (hr) |
| EP (3) | EP4374915A3 (hr) |
| JP (2) | JP2020506180A (hr) |
| KR (2) | KR20240096848A (hr) |
| CN (2) | CN116327958A (hr) |
| AU (2) | AU2018213147B2 (hr) |
| BR (1) | BR112019015368A2 (hr) |
| CA (1) | CA3051374A1 (hr) |
| DK (2) | DK3573620T3 (hr) |
| ES (2) | ES2981657T3 (hr) |
| FI (2) | FI4101454T3 (hr) |
| HR (2) | HRP20240701T1 (hr) |
| HU (1) | HUE061444T2 (hr) |
| LT (2) | LT3573620T (hr) |
| MX (2) | MX2019008813A (hr) |
| PL (2) | PL4101454T3 (hr) |
| PT (2) | PT3573620T (hr) |
| RS (2) | RS65701B1 (hr) |
| RU (1) | RU2019126749A (hr) |
| SI (1) | SI3573620T1 (hr) |
| TW (3) | TW201831204A (hr) |
| WO (1) | WO2018138578A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10369156B2 (en) | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| BR112019015368A2 (pt) | 2017-01-25 | 2020-03-10 | The George Institute for Global Health | Composições para o tratamento de hipertensão |
| JP2021536443A (ja) * | 2018-08-25 | 2021-12-27 | シーアールディー ファーマシューティカルズ インコーポレイティド | 高血圧治療をサーカディアンリズムと同期させる |
| CN111789843A (zh) * | 2019-04-08 | 2020-10-20 | 深圳奥萨医药有限公司 | 含氨氯地平、氯噻酮和阿米洛利的药物组合物 |
| CN113616651B (zh) * | 2020-05-08 | 2023-12-29 | 深圳奥萨制药有限公司 | 一种复方降压药物组合物及其应用 |
| US11730706B1 (en) * | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT199800126A (es) | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
| DK1272220T4 (en) | 2000-04-10 | 2016-11-28 | Nicholas John Wald | Cardiovascular disease prevention formulation |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| US20040198789A1 (en) * | 2003-02-28 | 2004-10-07 | Recordati Ireland Limited | Lercanidipine/ARB/diuretic therapeutic combinations |
| US20050187262A1 (en) * | 2004-01-12 | 2005-08-25 | Grogan Donna R. | Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use |
| US20070191438A1 (en) | 2004-04-06 | 2007-08-16 | Rohrer Susan P | Methods for the treatment of hypertension |
| KR100582347B1 (ko) | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
| US20070196510A1 (en) | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| MX2008011872A (es) | 2006-03-16 | 2009-02-10 | Metabolic Solutions Dev Compan | Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos. |
| CA2655144A1 (en) | 2006-06-15 | 2007-12-21 | Gilead Colorado, Inc. | Antihypertensive therapy method |
| EP2190433A2 (en) | 2007-08-22 | 2010-06-02 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
| KR20090057538A (ko) * | 2007-12-03 | 2009-06-08 | 박사룡 | 안지오텐신 투 안타고니스트, 칼슘 안타고니스트 및이뇨제를 함유하는 고혈압 치료제 조성물 |
| CN101450211A (zh) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | 复方降压制剂 |
| DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| MY198422A (en) | 2009-04-29 | 2023-08-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| CN101966187A (zh) * | 2009-07-14 | 2011-02-09 | 邬林祥 | 一种治疗高血压含氨氯地平和厄贝沙坦的复方制剂 |
| CN101618215A (zh) | 2009-08-16 | 2010-01-06 | 王丽燕 | 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物 |
| WO2011149438A1 (en) * | 2010-05-28 | 2011-12-01 | Mahmut Bilgic | Combination of antihypertensive agents |
| CN101966190A (zh) * | 2010-07-17 | 2011-02-09 | 邬林祥 | 一种治疗高血压含氨氯地平和依普罗沙坦的复方制剂 |
| CN102225203A (zh) * | 2011-06-29 | 2011-10-26 | 北京阜康仁生物制药科技有限公司 | 一种用于降低血压的药用组合物 |
| CN102327272B (zh) | 2011-07-14 | 2013-08-14 | 海南锦瑞制药股份有限公司 | 一种口服固体药用组合物及其制备方法 |
| US10918612B2 (en) * | 2013-01-22 | 2021-02-16 | Markus Zwickl | Combinations with 2-aminoethanesulfonic acid |
| US9839644B2 (en) * | 2014-09-09 | 2017-12-12 | ARKAY Therapeutics, LLC | Formulations and methods for treatment of metabolic syndrome |
| CZ2015687A3 (cs) | 2015-10-02 | 2017-04-12 | Zentiva, K.S. | Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu |
| CN106310278A (zh) * | 2016-08-01 | 2017-01-11 | 深圳奥萨制药有限公司 | 一种含叶酸的多联降压药物组合物 |
| US10369156B2 (en) | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| BR112019015368A2 (pt) | 2017-01-25 | 2020-03-10 | The George Institute for Global Health | Composições para o tratamento de hipertensão |
| CA3107616A1 (en) | 2018-07-26 | 2020-01-30 | The George Institute for Global Health | Compositions for the treatment of hypertension |
-
2018
- 2018-01-23 BR BR112019015368-3A patent/BR112019015368A2/pt active IP Right Grant
- 2018-01-23 PL PL22188172.5T patent/PL4101454T3/pl unknown
- 2018-01-23 CA CA3051374A patent/CA3051374A1/en active Pending
- 2018-01-23 DK DK18745362.6T patent/DK3573620T3/da active
- 2018-01-23 ES ES22188172T patent/ES2981657T3/es active Active
- 2018-01-23 LT LTEPPCT/IB2018/000083T patent/LT3573620T/lt unknown
- 2018-01-23 HR HRP20240701TT patent/HRP20240701T1/hr unknown
- 2018-01-23 JP JP2019539974A patent/JP2020506180A/ja active Pending
- 2018-01-23 FI FIEP22188172.5T patent/FI4101454T3/fi active
- 2018-01-23 HR HRP20230267TT patent/HRP20230267T1/hr unknown
- 2018-01-23 HU HUE18745362A patent/HUE061444T2/hu unknown
- 2018-01-23 ES ES18745362T patent/ES2940316T3/es active Active
- 2018-01-23 DK DK22188172.5T patent/DK4101454T3/da active
- 2018-01-23 EP EP24164449.1A patent/EP4374915A3/en active Pending
- 2018-01-23 AU AU2018213147A patent/AU2018213147B2/en active Active
- 2018-01-23 RS RS20240644A patent/RS65701B1/sr unknown
- 2018-01-23 PL PL18745362.6T patent/PL3573620T3/pl unknown
- 2018-01-23 KR KR1020247019312A patent/KR20240096848A/ko not_active Application Discontinuation
- 2018-01-23 SI SI201830873T patent/SI3573620T1/sl unknown
- 2018-01-23 MX MX2019008813A patent/MX2019008813A/es unknown
- 2018-01-23 RS RS20230204A patent/RS64042B1/sr unknown
- 2018-01-23 CN CN202310463571.8A patent/CN116327958A/zh active Pending
- 2018-01-23 CN CN201880021071.6A patent/CN110545819A/zh active Pending
- 2018-01-23 FI FIEP18745362.6T patent/FI3573620T3/fi active
- 2018-01-23 PT PT187453626T patent/PT3573620T/pt unknown
- 2018-01-23 WO PCT/IB2018/000083 patent/WO2018138578A1/en unknown
- 2018-01-23 EP EP22188172.5A patent/EP4101454B1/en active Active
- 2018-01-23 EP EP18745362.6A patent/EP3573620B1/en active Active
- 2018-01-23 PT PT221881725T patent/PT4101454T/pt unknown
- 2018-01-23 KR KR1020197024682A patent/KR20190127691A/ko active Application Filing
- 2018-01-23 RU RU2019126749A patent/RU2019126749A/ru unknown
- 2018-01-23 LT LTEP22188172.5T patent/LT4101454T/lt unknown
- 2018-01-25 TW TW107102631A patent/TW201831204A/zh unknown
- 2018-01-25 TW TW109105655A patent/TWI825279B/zh active
- 2018-01-25 TW TW112142923A patent/TW202421198A/zh unknown
- 2018-03-13 US US15/919,923 patent/US10322117B2/en active Active
-
2019
- 2019-04-24 US US16/393,774 patent/US10799487B2/en active Active
- 2019-07-24 MX MX2023004366A patent/MX2023004366A/es unknown
-
2020
- 2020-09-08 US US17/014,358 patent/US11478462B2/en active Active
-
2022
- 2022-09-16 US US17/932,982 patent/US12102623B2/en active Active
- 2022-12-14 JP JP2022199757A patent/JP2023063282A/ja active Pending
-
2023
- 2023-08-08 US US18/446,268 patent/US20230381161A1/en active Pending
- 2023-11-27 AU AU2023274064A patent/AU2023274064A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230267T1 (hr) | Pripravci za liječenje hipertenzije | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| CY1115652T1 (el) | Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες | |
| MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
| EA200701923A1 (ru) | Лекарственная форма для перорального введения витамина | |
| HRP20230935T1 (hr) | Postupci za liječenje i profilaksu hiv-a i aids-a | |
| MX2010007281A (es) | Composiciones farmaceuticas de amlodipina y valsartan. | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| HRP20221344T1 (hr) | Novi pripravak acetaminofenskog spoja bez nuspojave po jetru | |
| PH12014502609B1 (en) | Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug | |
| EA200500672A1 (ru) | Содержащие альфузозин композиции с отсроченным высвобождением | |
| WO2018069805A3 (en) | Method for preparation of liquid oral composition of l-thyroxin | |
| RU2017113827A (ru) | Фармацевтический состав для уменьшения спазмов мочевого пузыря и способ его применения | |
| JP2017515858A5 (hr) | ||
| RU2017115341A (ru) | Фармацевтическая композиция, содержащая бета-блокатор и ингибитор ангиотензинпревращающего фермента | |
| MD4877B1 (ro) | Compoziţie farmaceutică şi comprimat oral de S-adenozilmetionină cu eliberare întârziată | |
| RU2018110622A (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ И ИНГИБИТОР АПФ | |
| WO2020032883A3 (en) | Synergistic effects of a novel ketoprofen formulation including a gastro protective agent | |
| RU2017129085A (ru) | Новый состав N-карбамоилметил-4-фенил-2-пирролидона | |
| WO2020013776A3 (en) | Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation | |
| TR201722039A2 (tr) | Mesalazi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari | |
| WO2020018048A3 (en) | An immediate release pharmaceutical composition of anti-inflammatory drugs, famotidine and a carbonate | |
| RU2018140193A (ru) | Фармацевтическая композиция, содержащая бета-блокатор, ингибитор превращающего фермента и гипотензивное средство или нпвс | |
| JP2017515849A5 (hr) | ||
| CO2019013645A2 (es) | Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas |